Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 2D-to-3D Culture and Organoids 2020

2D-to-3D Culture and Organoids 2020 Agenda

Print Agenda

Wednesday, 25 March 2020


Yu-Chi ChenKeynote Presentation

Phenotypic Machine Learning in High Content Imaging Screening with Organoids
Yu-Chi Chen, Scientist, Bioprinting Group, NCATS, United States of America

In the last few years, there has been a fast increase in the use of 3D cellular models as physiological relevant assays for drug discovery and development.  The use of U-bottom plates has been widely used for growing 3D spheroids because they facilitate spheroid formation in a scalable and reproducible manner to enable large scale compound screening.  However, the U-bottom shape of the wells in these plates limits the use of high-resolution imaging (>20X) and high-content screening mainly due to light diffraction.  Therefore, the assays used for screening with spheroids have mostly been restricted to simple readouts such as cell viability using standard well-based assays, or high content assays measuring total fluorescence intensity.  As more complex spheroids and organoids models are developed for disease modeling, there is an increased need to be able to quantitate the effects of compounds in different cell types, sub-cellular biomarkers and phenotypes within these 3D systems.  Here we will discuss the development of a 1536-well 3D HCS assay platform that enables the generation of high-resolution sub-cellular images coupled with a Phenotypic machine learning and 3D segmentation analysis within 3D spheroids that enables the implementation of 3D High Resolution Imaging Screening.


Terry RissConference Chair

Title to be Confirmed.
Terry Riss, Global Strategic Marketing Manager Cell Health, Promega Corporation, United States of America


Gary GintantKeynote Presentation

Title to be Confirmed.
Gary Gintant, Senior Research Fellow, Abbvie, United States of America


Matthias von HerrathKeynote Presentation

Modeling Immune Mediated Beta Cell Destruction in Human Type 1 Diabetes with Organoids
Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, Professor, La Jolla Institute, United States of America

In the past 15 years we have been studying the pathology of human type 1 diabetes with access to donor pancreata through the human pancreatic organ donor consortium (nPOD). These studies have led to several findings, for example that certain cytokines are generated by beta cells themselves, sometimes under stress, and also that there are probably key factors that render beta cells susceptible to immune attacks. Mechanistically, the importance and meaning of these observations needs to be addressed in a suitable and easily manipulable in vitro system consisting of human islets and immune cells. We have built such a system in collaboration with the company InSphero and will discuss emerging findings.


Donna MendrickKeynote Presentation

Alternative Models Use: Regulatory Context
Donna Mendrick, Associate Director of Regulatory Activities, US Food and Drug Administration (FDA), United States of America

In 2017 FDA published the Predictive Toxicology Roadmap ( framework for integrating predictive toxicology methods into safety and risk assessments.  FDA welcomes data from alternative methods and is working internally and externally to learn more about technologies such as MPS.  This presentation will provide an overview of MPS work being done within FDA and the actions being taken to help move alternative assays into a regulatory context.


Tissue Organoids For Disease Modeling
Shay Soker, Professor of Regenerative Medicine, Wake Forest Institute for Regenerative Medicine, United States of America

Traditional in vitro two dimensional (2D) cell cultures fail to recapitulate the microenvironment of in vivo tissues. They have three major differences from native tissue microenvironments: substrate topography, substrate stiffness, and most importantly, a 2D rather than three dimensional (3D) architecture. In contrast, 3D human tissue organoids replicate native tissue structure and function and thus are superior to traditional 2D cultures and animal models. These organoids can be studied in vitro for several weeks to allow intensive investigations. Besides their advantages in drug toxicity testing and for development of new drugs, the human tissue organoid platform serves as a model system to explore human tissue development and disease. Our recent research was focused on the use of human tissue organoids to study liver development and congenital diseases as well as other common diseases such as tissue fibrosis and cancer. Altogether our human tissue organoids system can be used for modeling of a wide verity of diseases and develop new personalized/precision medicine applications.

Agenda is not currently available
Add to Calendar ▼2020-03-25 00:00:002020-03-26 00:00:00Europe/London2D-to-3D Culture and Organoids 20202D-to-3D Culture and Organoids 2020 in Boston, USABoston,